Pfizer (PFE) EBIT Margin (2009 - 2026)

Pfizer (PFE) has reported EBIT Margin for 18 consecutive years, with 28.37% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT Margin fell 611.0% year-over-year to 28.37% in Q2 2026; TTM through Jun 2026 was 32.02%, a 192.0% increase from a year earlier, with the FY2025 full-year figure at 33.13%, up 514.0% from the prior year.
• EBIT Margin was 28.37% for Q2 2026 at Pfizer, down from 37.04% in the prior quarter.
• Over five years, EBIT Margin peaked at 47.01% in Q3 2022 and troughed at 410.16% in Q4 2023.
• A 5-year average of 2.13% and a median of 35.31% in 2025 frame the typical range for EBIT Margin.
• Across the five-year window, EBIT Margin sank 2079 bps in 2023 and soared 1704 bps in 2025, its largest moves.
• Over 5 years, EBIT Margin stood at 47.01% in 2022, then sank by 972 bps to 410.16% in 2023, then surged by 107 bps to 30.55% in 2024, then declined by 20 bps to 24.56% in 2025, then increased by 16 bps to 28.37% in 2026.
• The last three EBIT Margin figures came in at 28.37% (Q2 2026), 37.04% (Q1 2026), and 24.56% (Q4 2025), per Business Quant data.